CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Pasireotide LAR +2 moredrug
Likely dose
Pasireotide LAR 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01563354
NCT01563354Phase 2Completed
CompareCT.gov

Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial

Novartis Pharmaceuticals·interventional·Posted Mar 27, 2012·Updated Apr 2, 2021

In Brief

A Phase 2 clinical trial evaluating Pasireotide LAR, Everolimus, and 1 other intervention for Neuroendocrine Carcinoma of the Lung and Thymus. Completed, enrolled 124 participants across 36 sites in 9 countries.

Detailed Summary

This was a multicenter, randomized, phase II study evaluating Everolimus or Pasireotide LAR alone or in combination in adult patients with advanced (unresectable or metastatic) neuroendocrine carcinoma of the lung and thymus

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Carcinoma of the Lung and Thymus
CountriesDenmark, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 27, 2012
Enrollment StartAug 16, 2013
Primary CompletionFeb 10, 2020
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 14.3 years ago

Interventions

Pasireotide LARdrug

60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1

Everolimusdrug

10 mg tables administered orally once a day

Pasireotide LAR and Everolimus Combinationdrug

Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily